Author Archives: admin


22.5% Growth Rate for Synthetic Stem Cells Market by 2028 | Overview, Top Technologies, Key Insights and Company Profiles – News Times

Get Instant Free Sample Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1799811

According to Market Study Report, Synthetic Stem Cells Market provides a comprehensive analysis of the Synthetic Stem Cells Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. This report also provides market landscape and market share information in the Synthetic Stem Cells Market. An exclusive data offered in this report is collected by research and industry experts team.

Top Key Players Profiled in the Synthetic Stem Cells Market include are North Carolina State University (NCSU) (US) and Zhengzhou University (China).

Synthetic Stem Cells Market is expected to grow from US$ 14 Million in 2023 to US$ 37 Million by 2028, at a CAGR of 22.5% during the forecast period. The synthetic stem cells market is driven by various factors such as ethical concerns regarding embryonic stem cells and the risk of tumor formation and immune rejection of natural stem cells.This report spread across 55 Pages, profiling 02 companies and supported with tables and figures are now available in this research.

The neurological disorders segment is expected to witness the highest CAGR during the forecast period.

The neurological disorders application is the faster-growing segment in the overall synthetic stem cells market. Based on application, the synthetic stem cells market is segmented into cardiovascular diseases, neurological disorders, and other diseases that include various cancers, wounds and injuries, musculoskeletal disorders, and blood disorders that require regenerative therapies.

Make Enquiry @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1799811

North America is expected to record the highest growth rate during the forecast period.

Countries in North America are constantly modernizing their healthcare infrastructure by investing in advanced therapies. The increasing prevalence of target diseases, focus on development of for regenerative medicines, fast adoption of advanced therapies, and regulatory support for stem cell therapies will result in the high rate of adoption of synthetic stem cell therapies in this region by 2023.

The Study Objectives of this report are:

Coupon Code Available for 20% Discount@ https://www.reportsnreports.com/purchase.aspx?name=1799811 .

Reason to access this report:

The report will provide the market leaders/new entrants in this market with information on the closest approximations of the revenue of the overall synthetic stem cells market and its sub segments. This report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and plan suitable go-to-market strategies. The report will also help stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

Follow this link:
22.5% Growth Rate for Synthetic Stem Cells Market by 2028 | Overview, Top Technologies, Key Insights and Company Profiles - News Times

Stem Cell Injections: What Are They & Does Stem Cell Therapy Work

The headlines sound almost too good to be true: Researchers Stunned by Stem Cell Experiment That Helped Stroke Patient Walk; Wife Recovered From Cancer After Pioneering Stem Cell Treatment; Stem Cell Transplant Trial Has Miraculous Effect on Multiple Sclerosis Sufferers.

Indeed, even experts are excited about these miracle cells, which are abundant in the body and can repair and replace all kinds of tissue. Theres no doubt in my mind that stem cells are going to revolutionize the way medicine is practicedwith the same kind of impact that antibiotics and vaccinations hadgetting at the root causes of disease rather than dancing around the periphery, says Charles Murry, M.D., Ph.D., director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington in Seattle.

But when it comes to medical research, Dr. Murry cautions, stem cells are barely at the starting gate. Despite their hitting the petri dish more than 20 years ago, many big questions remain: Which people, with which diseases, might benefit from their use? What types of stem cells should be used? How can the cells be manipulated and administered for lasting effect? And how does the treatment work? Exciting as the clinical trials are, most of those that have been completed so far are just at the phase one stage, in which researchers test a small number of people to see if an intervention is safe, not yet whether its effective.

What actually is too good to be true, then, are the claims being made by many of the for-profit stem cell clinics that have proliferated in the U.S. (more than 700 and counting). Using nothing more than very early study results and testimonials, these clinics promise thatfor thousands or tens of thousands of dollarsthey can use your own stem cells to treat everything from MS and rheumatoid arthritis to heart disease, diabetes, damaged joints, and cancer. Some offer cosmetic stem cell face-lifts or cellular breast and buttock jobs; others promise to boost athletic prowess.

Theres a striking gap between the claims these centers are making and the research thats been done for most of these diseases, says Leigh Turner, Ph.D., an associate professor in bioethics at the University of Minnesota who studies these clinics. People need to be very cautious about this treatment right now.

Most of the cells in our bodies are specific types of cellsheart, lung, muscle, nerve, blood, and more. But stem cells are undifferentiated, which means they have the potential to turn into more stem cells or other types of cells. Stem cells also can divide indefinitely and replace worn-out tissue, giving them the ability to become other cells and the potential to act as a ready repair system for the body.

What it's like to have stem cells injected into your face for younger-looking skin:

Stem cells generate so much buzz because they have the unique ability to turn into different types of cells. This means they have the potential to rebuild organs that are diseased, which in the medical field is known as regenerative medicine. Early on, scientists focused on stem cells taken from embryos because those cells naturally transform into the myriad ones that develop into the babys tissues and organs. But ethical issues and federal regulations related to these cells sent researchers scrambling to find alternatives.

Today, cutting-edge scientists are working to coax adult blood cells to become nascent cells akin to the embryonic kind by adding certain DNA molecules. These induced pluripotent stem cells, which have shown early promise, generally require months of careful manipulation in a lab and thus are mainly limited to top medical centers. Most of the for-profit clinics have settled on using cells taken from fully developed tissue, known as adult stem cells. By using cells from a persons own body, these clinics can complete a treatment in a day or a few weeks. Doctors typically liposuction a little fat or remove some bone marrow (which is an especially rich source of stem cells), put it through a few steps to remove other tissue, then inject the stem cells where they want them to proliferate. Someone whos coming in with arthritic hip pain, for example, might have cells removed from her belly and inserted into her hip.

Critics say the for-profit clinics that currently claim they can treat all manner of disease with adult stem cells are not being honest. Much more study is needed before any of these claims can be substantiated, says Kapil Bharti, Ph.D., a research scientist at the National Eye Institute of the National Institutes of Health who is at the leading edge of research on using pluripotent cells to treat macular degeneration. The problem with the cells is what we dont know. Those clinics inject the cells and hope they will secrete something beneficial, but every time they do the injections, theyre rolling the dice, he says.

The scientific consensus is that stem cells taken from fat or bone marrow are not as malleable as embryonic cells, meaning that rather than turn into completely different cells, they mostly create more of the same tissue. There is zero evidence, for example, that bone marrow tissue can make eye tissue, even though many of these clinics say it can. The cells dont integrate, so they die off, Bharti saysand the injections may cause significant damage in the process.

At the moment, stem cell treatments are medically recommended only for a small number of blood disorders. To treat leukemia, for example, patients typically have their bone marrow harvested before their bodies are blasted with high-dose chemotherapy. The stem cells from the marrow are then reinserted into the bloodstream to restore damaged cells there.

Early-stage research involving other conditions reveals why physicians are so excited about the methods future prospects. A very small industry-funded clinical trial in Australia found that in people who had the anterior cruciate ligament (ACL) in the knee reconstructed, those who subsequently had stem cells injected into their knees had less pain and better physical results on their MRIs than did a control group. An ongoing multiyear study of 110 patients with relapsing-remitting MS is finding that those treated with stem cells from their own bone marrow (along with some chemotherapy and/or radiation) are much less likely to have their disability worsen than those on standard disease-modifying drugsan incredible 6% versus 60%.

The potential to help her severe MS was what drove SammyJo Wilkinson of Edmonds, WA, to seek out stem cell treatment from a for-profit clinic in 2012. Wilkinson was desperate for something that might improve a disease that had forced her to shutter her thriving technology company and go on disability a decade earlier. After researching clinics, she settled on one in Texas (later relocated to Mexico). She liked that the clinic was up-front that the procedure was experimental and that her stem cells were banked for future rounds.

Six years and five treatments later, Wilkinson is happy with the results, even though major symptoms, including blindness in her right eye and the inability to walk without a wheelchair, remain. But of the 28 symptoms she said had decimated her life, 17 have disappeared, from fatigue and brain fog to numbness in her hands. My quality of life is so much better. No current medication can do what this treatment did, she says. Still, when other women with MS call her for advice, she lets them know that she is not curedand that the cost of her treatments ($90,000 plus travel expenses, none of it covered by insurance) was staggering.

While Wilkinson was lucky that she had positive results, this isnt true for many others. Thats one reason stem cell scientists are angry that the Food and Drug Administration hasnt come down harder on for-profit clinics. Between 2011 and 2017, the FDA issued some warning letters, and the Department of Justice filed for injunctions against only two clinics (one with multiple locations) this past May. In December 2018, the FDA issued yet another warning after 12 patients fell seriously ill after receiving stem cell injections. Litigation is ongoing, although the clinics can still see patients.

For-profit clinics point out that the FDA differentiates between drugs that need to go through the multiyear, multimillion-dollar approval process and those that use minimally manipulated substances taken from a persons own body, which dont. The clinics claim their treatments fall into the latter category, though critics say theyre manipulated much more heavily than the FDA intended for nondrug treatments. This has come to be a really important line, and many for-profit businesses claim theyre on the right side of it when realistically they arent, says Paul S. Knoepfler, Ph.D., a professor at the UC Davis School of Medicine who runs The Niche (ipscell.com), a blog that sheds light on the industry.

It might seem that theres no danger in receiving a treatment using your own cells, but that isnt the case. People have suffered very serious complications, Turner says. An article in Nature counts nine lawsuits in which people alleged that their treatmentsfor diabetes, lupus, lung disease, cosmetic surgery, and morecaused them harm. A report in the New England Journal of Medicine described three women with macular degeneration whose vision significantly worsened (two are now legally blind) when stem cells harvested from belly fat were injected into their eyes. Several stem cell clinic patients have died.

And those are just the people we know aboutside effects and serious complications dont have to be reported by the clinics, Turner says. Whats more, once-promising treatments have been shown to be potentially dangerous. Doctors were initially excited to think stem cells might repair diseased hearts, but a 2017 study on mice found that when the cells were injected, they turned inflammatory and worsened heart disease. (More research is being done.)

Another big issue is money. The fees Wilkinson paid are typical, and even cheaper therapies can feel like a rip-off. Although one injection of stem cells several years ago helped Olympic track and field hurdler LaVonne Idlette heal tendinitis in her knee, when she went back to treat a pulled hamstring muscle, another injection did nothing. At $1,200 a shot, it was ridiculously expensive, says the 32-year-old Miami resident, now an attorney.

If you want to look into stem cell treatment, experts say the best way is to ask your doctor whether any reputable medical centers are conducting clinical trials focused on your disease. You can find trials at the National Institutes of Healths website clinicaltrials.gov, but theres another caveat: Some clinics say theyre doing a patient-funded study, and theyll even list it on the government website, but when you look at the details, there are a lot of red flags, Turner says. One of those is being asked to pay thousands of dollars to participate (reputable studies typically ask only that you pay your own travel fees). Turner also doubts that data from these so-called trials are being tabulated; he and others say some clinics are simply trying to legitimize risky treatments.

Beyond entering a trial youre sure is being done properly, experts say that for now you should steer clear. Mayo Clinic has started a regenerative medicine consult service and tells patients this: The current standard of care for nearly all medical conditions is still the best. If you have arthritis in your knees, for example, physical therapy, medication, or even knee replacement surgery will give you much better odds than experimental stem cell treatments, says Shane Shapiro, M.D., program director at Mayo Center Regenerative Medicine Therapeutic Suites.

Of course, clinics point to success stories as reasons to try their stem cell therapies. Seven years ago, Amy Klein, a freelance writer in New York City, received a stem cell face-lift to get rid of a tired complexion and dark bags under her eyes. Stem cells were taken from her stomach fat and injected into her face. So many years later, my skin still looks really good. Not only are my bags gone, but the quality of my skin is back to the dewy tightness of my youth, she says.

But when small numbers of patients claim good results, scientists call it anecdotal medicine and stress that its not strong enough evidence to base treatment advice on. Before you can call something a success, you have to repeat your findings with a large number of patients over a long period of time, Dr. Shapiro says. Until those major studies are done and its proven that stem cells are safe and effective for the conditions for which theyre being advertised, patients are simply rolling the dice.

Despite warnings, some patients with serious degenerative diseases who have tried all the conventional treatments choose for-profit stem cell clinics. If someone thinks its better to take a low-percentage shot as opposed to waiting for a degenerative disease to progress, that may not be an entirely irrational way to view things, says Dr. Murry. The problem is, its nearly impossible for the average patient to evaluate whether an unproven treatment has evidence for safety or efficacy. This is why the clinics need regulatory oversight.

How to protect yourself if you do decide to proceed:

See what the evidence shows. The federal database pubmed.gov lists results of most published studies. If you read reputable journals to see what the evidence reveals, youll be less likely to fall prey to a clinics overselling. If theres zero research on the use of stem cells for your condition, be especially concerned.

Know that some treatments are riskier than others. Procedures that inject cells into vital organs, like the brain, nervous system, heart, or eyes, have the potential to do more serious damage if the treatment goes awry than those aiming to fix joints or appearance.

Choose a clinic with care. If they tell you a treatment theyre selling has no risks, thats a big red flag: Theyre either woefully lacking in knowledge or not being honest, and I would walk away, says Paul S. Knoepfler, Ph.D. Keep your doctor informed. Youll want to let your physician know youre planning to do this, then see him or her soon after your treatment, Dr. Murry advises.

See the original post here:
Stem Cell Injections: What Are They & Does Stem Cell Therapy Work

Stem Cell Therapy | Stanford Initiative to Cure Hearing Loss

What if doctors could grow a new working inner ear from a persons own skin cells? Or repair the damaged inner ear from within?

Solving this profound mystery is the driving force behind stem cell research and the promise of tissue engineering in otolaryngology. While hearing aids and cochlear implants can provide good recovery of hearing function, the development of a biological method to repair the damaged cochlea has the potential to restore normal hearing without any type of prosthesis.

One approach to restore hearing might be to surgically place stem cells within the cochlea in such a way that they would fuse with the remaining cochlear structures and develop and function as hair cells. Scientists believe this is a viable approach because, unlike most organs that are destroyed by disease, the inner ear remains structurally intactonly the hair cells are lost. By mimicking the steps involved in the formation of embryonic mouse ears, Stanford scientists have produced stem cells in the laboratory that look and act very much like hair cells, the sensory cells that normally reside in the inner ear. If they can generate hair cells in the millions, it could lead to significant scientific and clinical advances along the path to curing deafness in the future.

A promising source of creating hair cells comes from induced pluripotent stem cells (iPS)adult cells, taken for example from a patients own skin that have been genetically reprogrammed to revert back to stem cells. This breakthrough process represents a major opportunity to eventually treat a patient with his or her own cells.

Currently, our research team is working toward producing human hair cells for the first time in a culture dish. This work could lead, in the long run, to novel therapies based on cell transplantation.

Equally exciting is an ongoing approach to use embryonic stem cell-based approaches for discovery of novel drugs that could be used for treatment for deafness. More about this exciting new direction can be found under Molecular Therapy.

Originally posted here:
Stem Cell Therapy | Stanford Initiative to Cure Hearing Loss

Does Medicare Cover Stem Cell Therapy in 2020? Find Out Here

Stem cell therapy has revolutionized the healthcare system. It has provided hopes for patients who suffer from diseases that were considered incurable and even some other acute and chronic diseases that had a lesser chance of recovery.

It can relieve the symptoms the patients are experiencing and also enhance the quality of their life. Here is a brief discussion about whether stem cell theory is covered by Medicare.

Medicare Plan A and B cover the costs of stem cell therapies when certain criteria are fulfilled. However, even in these cases, Medicare does not reimburse the full costs.

Stem cell therapies that involve blood-forming stem cells are approved by the FDA. And hence, only these therapies would be covered by Medicare. There are certain limits to the coverage of stem cells therapies depending on the types of stem cells used as discussed beneath:

Stem cells are the cells that are formed in the body at birth. The uniqueness of these cells is they can change into any type of cell found in any organ or tissue of the body. These cells have the ability to regenerate and form more cells of a similar type to heal the damaged tissues and organ. These cells play an important role in producing organs, ligaments, bones, muscles, tendons, joints and skin.

There are basically 4 main types of stem cells that the body can produce during its life.

HSCT or Hematopoietic Stem Cells are also a type of stem cell. Stem cell therapies using these cells would be covered by Medicare only when it is performed for conditions such as:

Autologous Stem Cell Transplantation is covered by Medicare Plan A and B when it is recommended for the management of the following conditions:

Stem Cell Therapy is not covered by Medicare to treat the following conditions:

When stem cell therapy is performed for the management of these conditions, it would not be covered by Medicare Plan A or B. For example; though Stem cell therapy is considered effective for the management of osteoarthritis of the knee joint, it is not covered by Medicare as it is not approved by the FDA,

Medicare beneficiaries who experience chronic pain due to osteoarthritis can check whether any other insurance plan covers the expenses of stem cell therapy.

They can check the coverage offered by Medicare Advantage Plans and sign up for one if they anticipate they might need to undergo the procedure in the future. They should also check the specific criteria that must be fulfilled in order to be eligible for the coverage.

Link:
Does Medicare Cover Stem Cell Therapy in 2020? Find Out Here

Novel stem cell therapy for repair of knee cartilage – Mayo …

Dec. 29, 2018

Mayo Clinic offers a unique regenerative medicine approach for repairing knee cartilage, which can be completed in a single surgery. The Food and Drug Administration approved the use of this technique, known as recycled cartilage auto/allo implantation (RECLAIM), in a trial utilizing the stem cell bank in the Mayo Clinic Center for Regenerative Medicine.

"Mayo is unique in having an adipose-derived allogeneic stem cell bank. It provides us with donor mesenchymal stem cells, which we mix with recycled autologous cells to quickly obtain enough cells to fill the patient's cartilage defect without operating twice," says Daniel B. Saris, M.D., Ph.D., an orthopedic surgeon at Mayo Clinic in Rochester, Minnesota, who specializes in knee surgery and focuses on regenerative medicine.

Close

RECLAIM mixes chondrons from debrided tissue with donor autologous stem cells to create a biologic filler for the repair of damaged knee cartilage. The procedure can be completed in a single surgery.

Dr. Saris previously performed the RECLAIM cartilage repair technique in Europe. "The results, about four years out, are very good comparable to or better than other cell therapies, except these patients achieve normal function after surgery about six months more quickly," he says.

Planning is underway for a clinical trial at Mayo Clinic. RECLAIM is used to repair symptomatic cartilage defects, usually resulting from trauma or an athletic injury. The procedure might be suitable for nonarthritic patients ages 18 to 50 who have fresh cartilage defects.

Existing cell therapy to repair knee cartilage generally involves surgically debriding the cartilage defect and then taking a biopsy of healthy cartilage from the patient. The biopsy is cultured in an outside laboratory, and the cultured cells are implanted weeks later. "We wanted to improve this technique because during the waiting period, the patient's life is on hold, costs increase and the logistics can be complex," Dr. Saris says.

RECLAIM's innovation starts with saving the patient's debrided tissue. "That tissue is always a bit frilly and is normally discarded," Dr. Saris says. "But we found that the cells in that tissue are still very viable. We recycle them."

The resected tissue is processed and, using a rapid isolation protocol, digested into chondrons. Mixing the chondrons with allogeneic stem cells from the stem cell bank provides sufficient cells to immediately re-inject into the patient.

"This is a highly innovative procedure," Dr. Saris says. "You have to find an intricate balance loading enough cells to grow into healthy tissue but not overloading the space so the cells are squished when the patient starts rehab."

Most patients return home on the day of surgery. They generally need to wait nine to 12 months before a full return to sports; that interval provides time for the cartilage to grow and the patient to regain muscle control. "But apart from sports, patients can go back to normal life within days and physical activities within three to four months of surgery," Dr. Saris says.

Mayo Clinic's multidisciplinary approach provides the range of care needed by patients at all stages of knee cartilage repair. Before surgery, advanced imaging helps pinpoint the cartilage defect. "Our physiotherapists and athletic trainers also determine prior to surgery how we can optimize the patient's musculoskeletal control and function, and then work with the patient on rehab after surgery," Dr. Saris says.

Mayo Clinic also has the breadth of orthopedic expertise to manage problems that patients often experience alongside damaged knee cartilage, such as varus deformity and anterior cruciate ligament or meniscus lesions. "If a cartilage repair procedure fails, it's generally because not enough attention was paid to other factors the meniscus or the knee's alignment or stability," Dr. Saris says. "Our unique multidisciplinary team looks at all aspects of a patient's care. Our chances of success for these complex biological reconstructions is therefore high."

The cartilage repair technique illustrates Mayo Clinic's commitment to applying regenerative medicine to orthopedic surgery. "We are focused on patient-centered progress," Dr. Saris says. "We want to make sure there is a safe and efficacious portfolio of regenerative medicine therapies for musculoskeletal problems."

Read the original post:
Novel stem cell therapy for repair of knee cartilage - Mayo ...

‘I’m not losing my boy,’ sobs mum after son is diagnosed with cancer for third time – Mirror Online

The Peers family were overjoyed when doctors told them Callum had beaten cancer.

Life returned to normal but, tragically, it would not stay that way.

The battling ten-year-old, who has twice successful fought cancer, has the disease once again.

This time the odds are heavily stacked against him. Doctors here give him just a ten per cent chance of living more than five years.

But his parents are determined to fight on and are pinning their hopes on pioneering drug trials.

They are trying to raise 150,000 to get Callum treatment in the US that is not available on the NHS.

Callums mum Nicola, 37, said: Seeing my son fight this disease for seven years has been heartbreaking but he has never given up.

Hes fought it and beaten it twice and I know he can do it again. We must give him that chance. I am not losing my boy.

Callum, of Leigh, Gtr Manchester, was just three when he began getting symptoms. Nicola first took Callum to his GP with stomach pains.

In June 2013, after hed turned four, he was diagnosed with an aggressive stage-4 neuroblastoma.

She said: It was such a shock when they told us, the last thing we expected. It was a body blow.

I was heartbroken but I had to carry on and be strong for Callum.

We told him he had a lump in his tummy and was having medicine for it. He was a little hero and never complained.

Callum had an operation to remove a tumour in his stomach and gruelling chemotherapy, immunotherapy and stem cell treatment.

He lost his hair, endured sickness, lethargy, high temperatures and spent months in hospital.

Then, in December 2014, the family got the news they were hoping for when his scans came back all clear.

Nicola recalled: We were over the moon. Life slowly went back to normal and we started going on family caravan holidays again.

But just over two years later, in January 2017, when Callum was getting ready for school he complained of feeling unwell.

Nicola noticed a lump on his neck. An emergency scan at the hospital confirmed the cancer had returned.

Nicola said: To get that news a second time was devastating. It could easily have broken us, but we had to fight on.

Callum had three types of chemo and after 12 months in and out of hospital he had kicked the cancer again.

But in August last year there was a lump on his neck and Nicola knew what to expect. The cancer had spread to the right side of his stomach. She said: Id thought after his treatment had finished the second time we were going to go back to normal.

Being told again and again your boy has cancer is awful.

Since then a tumour on Callums chest has been surgically removed and, days before his tenth birthday, another growing on his spine, which could have paralysed him, was taken out.

He has been through more chemo and radiotherapy, been rushed into intensive care with complications four times.

He spent his Christmas at Great Ormond Street hospital in London. Nicola said: Callum is the definition of a fighter. I know he can beat this again and beat it for good.

Treatment options in the UK for Callum have run out but Nicola and his dad Alan, 56, brothers Jake, 19, Joshua, 18, and Cameron, nine, and sister Bethany, 17, arent giving up hope.

Helen Devos Childrens Hospital in Michigan is one of the few centres offering a treatment that works by targeting specific cancer stem cell pathways. Nicola spoke to consultants there and said: Children are going over there and are still clear of disease years and years later.

Callum has been through so much. He just carries on and he deserves this chance.

Were all feeling really hopeful. Its been proven to work.

She added: I know Callum can win his fight if we can give him the best possible chance.

Originally posted here:
'I'm not losing my boy,' sobs mum after son is diagnosed with cancer for third time - Mirror Online

Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 – Monroe Scoop

Canine Stem Cell Therapy Market size will reach xx million US$ by 2029, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and2029 as the forecast period to estimate the market size for Canine Stem Cell Therapy.

This industry study presents the Canine Stem Cell Therapy Market size, historical breakdown data 2014-2019 and forecast 2029. The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Canine Stem Cell Therapy Market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/2360

Canine Stem Cell Therapy Market report coverage:

The Canine Stem Cell Therapy Market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Canine Stem Cell Therapy Market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The study objectives are Canine Stem Cell TherapyMarket Report:

In this study, the years considered to estimate the market size of Canine Stem Cell TherapyMarket:

History Year: 2014 2018

Base Year: 2018

Estimated Year: 2019

Forecast Year:2029

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Canine Stem Cell Therapy Market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/2360

The report covers exhaustive analysis on:

Regional analysis includes

Get Full Report Access athttps://www.xploremr.com/cart/2360/SL

Benefits of Purchasing from XMR:

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:

XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108E-mail id-[emailprotected]Web-https://www.xploremr.com

Read the original:
Canine Stem Cell Therapy Market to Witness Growth Acceleration During 2029 - Monroe Scoop

CytoDyn’s First mTNBC Patient in Phase 1b/2 is in Remission and Oncologist Ordered Termination of Treatment with Carboplatin (chemotherapy drug) and…

VANCOUVER, Washington, March 12, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA recommended that the Company request a preliminary Breakthrough Therapy designation meeting. Meanwhile, the Company continues reporting very positive data for its mTNBC and MBC patients.

Metastatic triple-negative breast cancer (mTNBC), an aggressive histological subtype, has a poor prognosis. In addition, metastatic breast cancer (MBC) is breast cancer that has spread beyond the breast and lymph nodes to other organs in the body (typically the bones, liver, lungs, or brain). Both types of cancer pose significant challenges for patients due to their aggressiveness and limited treatment options. An integral part of CytoDyns mission and purpose is to provide effective therapeutic solutions to these patients. Clinical results from the first cancer patient in the Companys Phase 1b/2 mTNBC trial are as follows:

Patient #1: Enrolled in mTNBC Phase 1b/2 with first treatment in late September 2019. CTC (circulating tumor cells) dropped to zero after two treatments with leronlimab and carboplatin. Total CTC and EMT (Epithelial Mesenchymal Transition in Tumor Metastasis) dropped to zero after about one month of treatment with leronlimab (once-a-week 350 mg dose). Results from the patients earlier CT scan indicated a more than 25% tumor shrinkage within the first few weeks of treatment with leronlimab and carboplatin. After approximately five months of treatment with leronlimab and carboplatin, the patient not only has zero CTC and zero EMT, but also zero detectible CAML (cancer-associated microphages like cells). The patients oncologist has now ordered this patients treatment to consist only of leronlimab and has discontinued treatment with carboplatin (a chemotherapy drug). Testimony provided to the Company from the patient stated: So far my experience with leronlimab has been very positive. I didnt expect it to be so easy and tolerable with virtually ZERO side effects. The results so far have been super impressive. Im very grateful to be part of this clinical trial study and it really makes me feel hopeful that this otherwise fatal disease can be turned into a manageable disease in the near future.

Bruce Patterson, M.D., chief executive officer and founder of IncellDx, a diagnostic partner and advisor to CytoDyn, commented, The FDA recommendation for a meeting on CytoDyns BTD application is a tremendous opportunity to further discuss the mechanism of action and to summarize the promising results from patients enrolled following the submission of the application. Included in this discussion will be the recent decision by the oncologist of Patient #1 to, based on continued unremarkable changes to her condition, remove carboplatin from the patients regimen with continued therapy with leronlimab. Nader Pourhassan, Ph.D., president and chief executive officer of CytoDyn, added: Our first patient in the Phase 1b/2 trial has shown remission of the tumor and her oncologist has attributed this primarily to leronlimab and discontinued the carboplatin (a form of chemotherapy). This patients latest results of zero CTC, EMT, and CAML is unique and we now have another patient with three zeros identical to the first patient. We are very excited to continue enrolling patients and hopeful to have our first patient treated in our basket trial for 22 solid tumor cancers very soon. We are also very hopeful to have several more patients in our Phase 1b/2 mTNBC trial before our preliminary meeting with the FDA for Breakthrough Therapy designation.

About Triple-Negative Breast CancerTriple-negative breast cancer (TNBC) is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer growthestrogen receptors (ER), progesterone receptors (PR) and the hormone epidermal growth factor receptor 2 (HER-2) gene. TNBC cancer occurs in about 10 to 20 percent of diagnosed breast cancers and can be more aggressive and more likely to spread and recur. Since the triple-negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.

About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) have granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including NASH. Leronlimab has successfully completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 plays an important role in tumor invasion and metastasis. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is therefore conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additional clinical studies when appropriate.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be important in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to further support the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD and that blocking this receptor from recognizing certain immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDyn CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. CytoDyn plans to seek FDA approval for leronlimab in combination therapy and plans to complete the filing of a Biologics License Application (BLA) in the first quarter of 2020 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients and plans to initiate a registration-directed study of leronlimab monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients, with some patients on leronlimab monotherapy remaining virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTS

Investors: Dave Gentry, CEO RedChip Companies Office: 1.800.RED.CHIP (733.2447) Cell: 407.491.4498 dave@redchip.com

Visit link:
CytoDyn's First mTNBC Patient in Phase 1b/2 is in Remission and Oncologist Ordered Termination of Treatment with Carboplatin (chemotherapy drug) and...

A new therapeutic approach against COVID-19 Pneumonia – Institute for Ethics and Emerging Technologies

The novel coronavirus disease 2019 (COVID-19) has grown to become a global public health emergency. Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially the severe cases. A new study offers a promising pathway for developing such a treatment.

The new approach involves intravenous transplantation of mesenchymal stem cells (MSCs) into the patients. It was successfully tested in 7 COVID-19 patients, in Beijing YouAn Hospital, Capital Medical University, China. The results are published in the scientific journal Aging and Disease, entitled "Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia".

http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml

The study was conducted by a team led by Dr. Robert Chunhua Zhao, with Shanghai University and Chinese Academy of Medical Sciences & Peking Union Medical College, China.

Moreover the study was reviewed by a scientific committee of the International Society on Aging and Disease (ISOAD) and the recently established UNESCO-affiliated committee on Anti-Aging and Disease Prevention http://www.aginganddisease.org/article/2020/2152-5250/ad-11-1-212.shtml

Based on the 14 days observation, MSCs could cure or significantly improve the functional outcomes of all the seven tested patients without observed adverse effects, contrary to 3 controls. The pulmonary function and symptoms of these seven patients were significantly improved after MSC transplantation. Among them, one severe and two common patients recovered and were discharged in 10 days after the treatment. The improvement was particularly dramatic for an elderly (65 y.o.) male patient in severe critical condition. All of his primary and secondary outcomes improved: the inflammation status, the oxygen saturation, and the functional biochemical indicators returned to normal reference values in 2~4 days after the treatment.

The presented evidence suggests that the therapeutic effects are based on the immunomodulatory capacity of mesenchymal stem cells (restoring the balance of the immune system). The coronavirus infection can stimulate a terrible cytokine storm in the lung, disrupting the balance of cytokines (signaling molecules of the immune system) such as IL-2, IL-6, IL-7, GSCF, IP10, MCP1, MIP1A and TNF cytokines, followed by the edema, dysfunction of the air exchange, acute respiratory distress syndrome, acute cardiac injury and the secondary infection, which may lead to death. The bone-marrow derived MSCs could inhibit the over-activation of the immune system and promote endogenous repair by improving the microenvironment, thus they could represent a safe and effective treatment for patients with COVID-19 pneumonia, especially for the patients in critically severe conditions. A larger validation study is required and is already underway, yet the initial results are encouraging.

Notably, the coronavirus-infected pneumonia is more likely to affect older individuals, especially older males, with comorbidities, resulting in their severe and even fatal respiratory diseases such as acute respiratory distress syndrome. In other words, aging appears to be the main risk factor for bad outcomes. However, the cure essentially depends on the patient's own immune system. When the overactivated immune system kills the virus, it produces a large number of inflammatory factors, leading to the severe cytokine storms. This suggests that the main reason for the organs damage may be the virus-induced cytokine storm. Older subjects may be much easier to be affected due to immunosenescence. The study showed remarkable recovery of the elderly patients thanks to restoring their immune function.

Thus, the study may have a broader significance, even beyond the treatment of the severe coronavirus disease. This study exemplifies that the general therapeutic improvement of the immune system in the elderly can improve outcome and survival, which may have more general relevance for other aging-related communicable diseases. Thus, this study may inspire and pave the way for further promising directions to investigate the connection between aging and disease, and to treat both communicable and non-communicable aging-related diseases.

The Romanian journalist Laura tefnu spoke with Dr. Ilia Stambler about the broader implications of this research. Ilia Stambler is a co-author in this study who was involved in the study review, interpretation and discussion. He serves as the Outreach Coordinator of the International Society on Aging and Disease (ISOAD) and Director of Research and Development at Shmuel Harofe Geriatric Medical Center in Israel.

Q: How does it feel to be part of the team which discovered a groundbreaking treatment for what is currently considered one of the biggest global challenges?

A: I feel very honored to be included in this extended international team. I hope this team continues its work that will also involve additional collaborations.

Q: As a researcher, what did you find most interesting about this novel coronavirus? What seems most threatening about this new virus?

A: The spreading ability of this virus is relatively high and it has the capacity to affect the entire global population. This is what makes this virus a particularly strong concern for global public health. The social effects of this epidemic are also of great importance. In a sense, this virus is testing the strength of our public health systems. Will the immunity of our public healthcare be strong enough to contain it? I hope it is.

Q: Did the discovery of this groundbreaking new therapeutic approach make you more optimistic (when it comes to containing and limiting the damage of Covid-19)? In which sense (where was your optimism before the discovery)?

A: I was optimistic before, as I believe that, same as for many infectious diseases in the past, also for this disease, effective therapeutic and preventive measures will be found and used. This work further increased my optimism. Of course, this is an initial study, and this is only one of the potential means in the therapeutic, preventive and hygienic arsenal. More research and confirmation will be needed. Yet, even at this stage, the clear positive result of this study shows that it is indeed possible to improve the outcomes for COVID-19 patients even in severe conditions. Moreover, it gives more hope that effective treatments can be sought and found also for other aging-related infectious diseases and conditions.

Q: Is there an explanation regarding the reasons why Covid-19 seems to pardon children and affects the most elder individuals, especially men?

A: There is yet no clear or fully agreed explanation. But a plausible cause may be due to the so called immuno-senescence phenomenon, or the inability of the aging immune system to cope with new threats and restore the immune balance following the infection. In men the immuno-senescence effects are often more strongly present than in women. Thus, aging appears to be the main risk factor for this disease and if we really wish to defeat this epidemic, we need to address this main risk factor, in other words, we need to therapeutically intervene and ameliorate the degenerative aging process. The proposed mesenchymal stem cell therapy shows the so-called immuno-modulation effects or the ability to generally improve the immune system, help restore the immune balance after disturbances, especially for the elderly. And this can be the more general explanation for its effects against the aging-related COVID-19 pneumonia, as well as potentially other aging-related diseases.

Q: How did you manage to find so fast a treatment that is responding so well?

A: The mesenchymal stem cell treatment has been researched and developed by Dr. Zhao and his team for many years, and indicated positive effects for multiple health conditions. It is exactly because of the common and critical role of the immune system impairment in all these conditions, that the treatment developed by Dr. Zhaos team was already in place and could be immediately used also for this condition dependent on the immune function. Moreover, the success of this therapy against COVID-19 can further boost the research and therapy of other immunity-dependent health conditions and diseases, especially aging-related diseases, due to the common mechanisms of action.

Q: How may this discovery change the game?

A: Unlike other public health measures, like quarantine and hygiene, that can be very quickly applied, the research, development, regulatory approval and application of new therapies is a much slower process. So we should first of all apply the public health measures to contain the epidemic. But the hope is that this therapy will undergo further research and validation as soon as possible, and in case of validated efficacy and safety, will be used in as many patients who need it as possible, as soon as possible. That is exactly why we need to accelerate the research, development and application of promising new therapies. When the new therapy enters wide clinical practice, there are grounds to believe it can improve the health and even save the lives of many patients, not only suffering from COVID-19, but also other conditions.

Q: Which was the response/reaction of authorities after you published the results of your research?

A: The outreach to the authorities in several countries has only started. Moreover, the study is only initial and it is too early to make policy recommendations. A larger validation study is required. Yet, if there is even a slight possibility this could become a life-saving therapy for COVID-19 patients and others, this opportunity should not be missed by the decision makers.

Q: Some treatments are more expensive than others. Will the treatment you discovered be accessible to people, or the cost for producing it will limit its accessibility?

A: The cells for this treatment can be mass produced and can be rather affordable. Of course, the actual price will depend both on the scale of production and pricing policies. And this is already a question that goes beyond pure technology, but becomes a question about the social means to make new therapies available to all. This should also be a crucial part of the public discussion about the social need to promote the rapid research and development as well as broad application of new therapies that are proven to be safe and effective.

Q: Which are the best measures a country can take to limit the spread and the consequences of the novel coronavirus?

The usual quarantine and public hygiene measures are the most feasible and effective: minimization of large gatherings, minimization of travel, cleanliness. We should hope and work for new effective therapies to arrive as soon as possible. But so far public health measures are the most effective and feasible.

Ilia Stambler is an IEET Affiliate Scholar. He completed his PhD degree at the Department of Science, Technology and Society, Bar-Ilan University. His thesis subject, and his main interest, is the History of Life-extensionism in the 20th Century.

Read more:
A new therapeutic approach against COVID-19 Pneumonia - Institute for Ethics and Emerging Technologies

Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing…

In this report, the global Cancer Stem Cell Therapy market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The Cancer Stem Cell Therapy market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Cancer Stem Cell Therapy market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2542097&source=atm

The major players profiled in this Cancer Stem Cell Therapy market report include:

The following manufacturers are covered:AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeAutologous Stem Cell TransplantsAllogeneic Stem Cell TransplantsSyngeneic Stem Cell TransplantsOther

Segment by ApplicationHospitalClinicMedical Research InstitutionOther

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2542097&licType=S&source=atm

The study objectives of Cancer Stem Cell Therapy Market Report are:

To analyze and research the Cancer Stem Cell Therapy market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Cancer Stem Cell Therapy manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Cancer Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the keyword market.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2542097&source=atm

Read more here:
Cancer Stem Cell Therapy Market Global Size, Demand-sales, Suppliers by Key Applications 2019 Detailed Analysis and Growth Aspects on Manufacturing...